Search Results - "JOHRI, Anandhi R"

Safety and Efficacy of Patupilone in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer: A Phase I, Open-Label, Dose-Escalation Study by TEN BOKKEL HUININK, Wim W, SUFLIARSKY, Jozef, SMIT, Willem M, SPANIK, Stanislav, WAGNEROVA, Maria, HIRTE, Hal W, KAYE, Stan, JOHRI, Anandhi R, OZA, Amit M

“…PURPOSE To evaluate the safety, maximum tolerated dose (MTD), and pharmacokinetics of patupilone administered once every 3 weeks with proactive standardized…”
Get full text

Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies by Orlowski, Robert Z., Voorhees, Peter M., Garcia, Reynaldo A., Hall, Melissa D., Kudrik, Fred J., Allred, Tammy, Johri, Anandhi R., Jones, Paul E., Ivanova, Anastasia, Van Deventer, Hendrik W., Gabriel, Don A., Shea, Thomas C., Mitchell, Beverly S., Adams, Julian, Esseltine, Dixie-Lee, Trehu, Elizabeth G., Green, Marie, Lehman, Mary Jo, Natoli, Susan, Collins, Jason M., Lindley, Celeste M., Dees, E.Claire

“…Proteasome inhibitors, a novel class of chemotherapeutic agents, enhance the antitumor efficacy of anthracyclines in vitro and in vivo. We therefore sought to…”
Get full text